Piramal Pharma Reaffirms Guidance and Plans $120 Million to $135 Million CapEx

Market snapshot: Piramal Pharma has reaffirmed its original full-year guidance for the CDMO business, supported by a strong opening order book in Q1. The company has mapped out a capital expenditure roadmap of $120 million to $135 million for the fiscal year, primarily focusing on its ongoing Lexington capacity expansion. The sterile injectables facility upgrade at Lexington is on schedule to achieve mechanical completion by the end of calendar year 2027.

Data Snapshot

• Annual capital expenditure guidance for the fiscal year is projected between US$120 million and US$135 million.
• First-quarter capital deployment stood at US$21 million, leaving the remaining budget to be ramped up dynamically over the subsequent quarters.
• Consolidated operations revenue surged 17% year-on-year to ₹2,270 crore, compared to ₹1,934 crore in the corresponding period of the prior year.

What's Changed

• EBITDA margins expanded significantly by approximately 400 basis points year-on-year, scaling to 12.5% in Q1 compared to 8.5% in the same period last year.
• Consolidated net loss narrowed to ₹69 crore from a loss of ₹82 crore in the corresponding quarter of the prior year, marking a steady recovery in bottom-line performance.

Key Takeaways

• Piramal Pharma's CDMO segment led the operational recovery with a 19% year-on-year revenue increase to ₹1,187 crore, supported by robust demand across Indian and international sites.
• The $120 million to $135 million CapEx program is highly targeted toward complex, high-margin capabilities, specifically focusing on sterile injectables compounding and payload linkers.
• The Lexington sterile injectables facility's expansion continues to head toward its end-of-CY2027 completion, adding crucial commercial-scale capabilities to service the growing onshoring demand.

SAHI Perspective

Piramal Pharma is demonstrating a structural operational turnaround. While the CDMO business typically shows seasonal H2-skewed performance, starting the fiscal year with a high-quality order book and a 19% top-line segment surge validates its full-year traction. The company's focus on high-barrier capabilities like Antibody-Drug Conjugates (ADCs) and sterile compounding at Lexington aligns cleanly with global onshoring demands, insulating it from tariff worries.

Market Implications

The positive traction in Piramal's CDMO pipeline indicates a broader recovery in global biopharma funding, which is now translating into solid Request for Proposal (RFP) momentum and higher conversion rates. This structural shift positions high-quality onshore manufacturing sites at a substantial premium.

Trading Signals

Market Bias: Bullish

Solid operating leverage is delivering on long-term targets, as highlighted by a 72% year-on-year increase in Operating EBITDA to ₹285 crore. Reaffirmed full-year guidance and an on-track CapEx model build strong confidence.

Overweight: Pharmaceuticals, CDMO Services

Trigger Factors:

• Progression milestones at the Lexington facility.
• Sustained RFP conversion and order book additions in the CDMO business during Q2.
• Improvement in subsidiary operational efficiency and forex mitigation.

Time Horizon: Medium-term (3-12 months)

Industry Context

The global pharma contract manufacturing landscape is witnessing a pivot toward high-value, niche modalities such as sterile compounding and active payloads. Shifting supply chain priorities, underscored by regulatory trends in Western nations, are driving outsourcing toward CDMOs with established, FDA-cleared local manufacturing capacities.

Key Risks to Watch

• Executing large-scale greenfield and brownfield expansions on tight timelines, where delays can affect early-stage commercial rollouts.
• Tax rate asymmetries and financial expenses arising from global operations, potentially acting as a near-term drag on consolidated net profits.

Recent Developments

In April 2026, Piramal Pharma received an Establishment Inspection Report (EIR) from the US FDA for its Lexington facility with Voluntary Action Indicated (VAI) classification, successfully closing previous inspections.

Closing Insight

As Piramal Pharma matches its capacity upgrades to an accelerating demand curve, the company is systematically building operating leverage. The validated $120 million to $135 million capital plan underpins its next leg of margin-rich growth.

High Performance Trading with SAHI.